LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Telix Pharmaceuticals Limited, (“Telix” or the "Company") (NASDAQ: TLX) investors off a class action on behalf of investors that bought securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). Telix investors have until January 9, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss thei ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations - The complaint alleges that Telix Pharmaceuticals materially overstated its progress with prostate cancer therapeutic candidates [2]. - It is claimed that the company overstated the quality of its supply chain and partners [2]. - As a result, the statements made by the defendants about Telix's business, operations, and prospects were materially false and misleading [2]. Group 2: Class Action Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025 [2]. - Shareholders are encouraged to register for the class action by January 9, 2026, to potentially be appointed as lead plaintiffs [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices [4]. - The firm is committed to ensuring companies adhere to responsible business practices and engage in good corporate citizenship [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the upcoming lead plaintiff deadline for a class action lawsuit set for January 9, 2026 [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by January 9, 2026, representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Telix's progress with prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - As a result of these misstatements, the lawsuit claims that investors suffered damages when the true information became public [5].

Core Viewpoint - Investors in Telix Pharmaceuticals Limited have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its business operations and prospects [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that between February 21, 2025, and August 28, 2025, Telix's defendants materially overstated the progress made with prostate cancer therapeutic candidates [3]. - The complaint also claims that the quality of Telix's supply chain and partners was materially overstated, leading to misleading positive statements about the company's business [3]. - As a result of these misrepresentations, the defendants' statements lacked a reasonable basis and were materially misleading at all relevant times [3]. Group 2: Participation Information - Investors who suffered losses in Telix Pharmaceuticals are encouraged to contact the Law Offices of Howard G. Smith before January 9, 2026, to participate in the ongoing lawsuit [2][4]. - Interested parties can reach out via email, telephone, or visit the law firm's website for more information regarding their legal rights and the class action [2][4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from February 21, 2025 to August 28, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3][6]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and success in this area [4].

Core Insights - The ZIRCON-X study indicates that nearly half of patients imaged with TLX250-CDx would experience a change in clinical management compared to standard imaging methods [1][2] - The study highlights the potential of TLX250-CDx to improve clinical decision-making in the management of indeterminate renal masses [5][6] Study Overview - ZIRCON-X was a non-interventional, prospective, post-hoc study involving 294 patients with indeterminate renal masses, assessing the impact of TLX250-CDx imaging versus standard contrast-enhanced imaging [2][6] - The study found that 143 patients (48.6%) would have had a change in clinical management, with over 20% potentially avoiding invasive biopsy [2][3] Clinical Management Changes - Among evaluable patients, 37.4% (110 out of 294) experienced major changes in clinical management, with approximately 30% having their treatment escalated or de-escalated [3] - The most common major changes included: - Biopsy to surgery (24 patients) - Surgery to biopsy (19 patients) - Additional diagnostic to surgery (18 patients) [4] Expert Commentary - Professor Karolien Goffin emphasized the significant potential of TLX250-CDx PET/CT to impact clinical decision-making for patients with small indeterminate renal masses [5] - Dr. David N. Cade noted that the analysis demonstrates the clinical usefulness of TLX250-CDx, which has been included in international guidelines for renal imaging [5] Product Information - TLX250-CDx is an investigational PET agent targeting carbonic anhydrase IX, expressed in over 95% of clear cell renal cell carcinoma (ccRCC) cells, providing high tumor-to-background imaging [8] - The pivotal Phase 3 ZIRCON trial showed TLX250-CDx achieved 86% sensitivity and 87% specificity for ccRCC [8]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Allegations Against Telix - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [5]. - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission, Telix's American Depositary Shares (ADSs) fell more than 13% over two trading sessions [6]. - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the FDA, which led to a further decline of over 21% in the price of its ADSs [7].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its prostate cancer treatment developments and supply chain strength [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025, with a deadline for lead plaintiff appointments set for January 9, 2026 [2]. - The complaint alleges that Telix overstated its progress in developing and commercializing prostate cancer treatments, leading to materially misleading public statements [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status at no cost [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - Telix Pharmaceuticals Limited is facing a class action lawsuit due to alleged securities fraud, with a deadline for investors to file a lead plaintiff motion by January 9, 2026 [1][5]. Summary by Sections Company Developments - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its disclosures related to prostate cancer therapeutic candidates, leading to a stock price drop of $1.70, or 10.4%, closing at $14.58 on July 23, 2025 [2]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA concerning its Biologics License Application (BLA) for TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package. This announcement caused the stock price to fall by $1.95, or 16.1%, closing at $10.15 on the same day [3]. Allegations in the Lawsuit - The class action complaint alleges that during the Class Period, Telix's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects. Specific allegations include: 1. Overstating the progress made on prostate cancer therapeutic candidates. 2. Overstating the quality of Telix's supply chain and partners. 3. Misleading investors regarding the company's business and operational prospects [4].

Group 1 - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. to recover losses for shareholders affected by alleged securities fraud between February 21, 2025, and August 28, 2025 [2][3] - The complaint alleges that the defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [3] - Shareholders who suffered losses during the relevant time frame are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4] Group 2 - Levi & Korsinsky LLP is a nationally recognized securities litigation firm with a track record of securing hundreds of millions of dollars for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [5]